JP2016505613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505613A5 JP2016505613A5 JP2015551250A JP2015551250A JP2016505613A5 JP 2016505613 A5 JP2016505613 A5 JP 2016505613A5 JP 2015551250 A JP2015551250 A JP 2015551250A JP 2015551250 A JP2015551250 A JP 2015551250A JP 2016505613 A5 JP2016505613 A5 JP 2016505613A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oral pharmaceutical
- composition according
- oil
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 28
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 9
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 8
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 8
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 6
- 239000012669 liquid formulation Substances 0.000 claims 6
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 230000037396 body weight Effects 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000003921 oil Substances 0.000 claims 4
- 235000019198 oils Nutrition 0.000 claims 4
- 108010039627 Aprotinin Proteins 0.000 claims 3
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 3
- 108010011459 Exenatide Proteins 0.000 claims 3
- 229960004405 aprotinin Drugs 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 229960001519 exenatide Drugs 0.000 claims 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 235000021323 fish oil Nutrition 0.000 claims 2
- 108090000317 Chymotrypsin Proteins 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 108010075530 Kunitz Soybean Trypsin Inhibitor Proteins 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 229940122618 Trypsin inhibitor Drugs 0.000 claims 1
- 101710162629 Trypsin inhibitor Proteins 0.000 claims 1
- 235000019498 Walnut oil Nutrition 0.000 claims 1
- 235000021302 avocado oil Nutrition 0.000 claims 1
- 239000008163 avocado oil Substances 0.000 claims 1
- 239000000828 canola oil Substances 0.000 claims 1
- 235000019519 canola oil Nutrition 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 229960002376 chymotrypsin Drugs 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000944 linseed oil Substances 0.000 claims 1
- 235000021388 linseed oil Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
- 239000008170 walnut oil Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IL2013/050007 WO2013102899A1 (en) | 2012-01-03 | 2013-01-03 | Methods and compositions for treating diabetes |
| ILPCT/IL2013/050007 | 2013-01-03 | ||
| US201361763996P | 2013-02-13 | 2013-02-13 | |
| US61/763,996 | 2013-02-13 | ||
| PCT/IL2014/050007 WO2014106846A2 (en) | 2013-01-03 | 2014-01-02 | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018131875A Division JP2018197240A (ja) | 2013-01-03 | 2018-07-11 | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016505613A JP2016505613A (ja) | 2016-02-25 |
| JP2016505613A5 true JP2016505613A5 (enExample) | 2017-01-05 |
Family
ID=51062529
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551250A Pending JP2016505613A (ja) | 2013-01-03 | 2014-01-02 | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
| JP2018131875A Pending JP2018197240A (ja) | 2013-01-03 | 2018-07-11 | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
| JP2020102461A Pending JP2020180126A (ja) | 2013-01-03 | 2020-06-12 | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
| JP2022156787A Pending JP2023002570A (ja) | 2013-01-03 | 2022-09-29 | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
| JP2025040577A Pending JP2025106279A (ja) | 2013-01-03 | 2025-03-13 | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018131875A Pending JP2018197240A (ja) | 2013-01-03 | 2018-07-11 | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
| JP2020102461A Pending JP2020180126A (ja) | 2013-01-03 | 2020-06-12 | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
| JP2022156787A Pending JP2023002570A (ja) | 2013-01-03 | 2022-09-29 | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
| JP2025040577A Pending JP2025106279A (ja) | 2013-01-03 | 2025-03-13 | Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20150335715A1 (enExample) |
| EP (2) | EP4215205A1 (enExample) |
| JP (5) | JP2016505613A (enExample) |
| CN (2) | CN104902921A (enExample) |
| WO (1) | WO2014106846A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2722054B1 (en) * | 2005-09-06 | 2018-03-21 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| RU2504373C2 (ru) | 2008-03-26 | 2014-01-20 | ОРАМЕД Лтд. | Способы и композиции для перорального введения протеинов |
| CA2723434C (en) | 2008-05-05 | 2018-01-23 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
| WO2013102899A1 (en) | 2012-01-03 | 2013-07-11 | Oramed Ltd. | Methods and compositions for treating diabetes |
| ES2912138T3 (es) | 2012-02-01 | 2022-05-24 | Oramed Ltd | Composiciones que contienen inhibidores de proteasa, composiciones que comprenden las mismas y métodos para producir y usar las misma |
| CN104902921A (zh) | 2013-01-03 | 2015-09-09 | 奥拉姆德有限公司 | 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物 |
| BR112015022762B1 (pt) | 2013-03-13 | 2022-08-16 | Takeda Pharmaceutical Company Limited | Composto de éster do ácido guanidinobenzóico, composição farmacêutica, e, uso do composto |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US10980866B2 (en) * | 2014-09-22 | 2021-04-20 | Hadasit Medical Research Services And Development Ltd. | Alpha-1 anti-trypsin for treating liver diseases |
| KR102399254B1 (ko) * | 2016-09-28 | 2022-05-17 | 아이거 바이오파마슈티컬스 인코포레이티드 | 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물 |
| CN109806386A (zh) * | 2017-11-20 | 2019-05-28 | 江苏恒瑞医药股份有限公司 | Fxr激动剂与glp-1类似物的药物组合物和用途 |
| MX2020013296A (es) * | 2018-06-11 | 2021-05-27 | Oramed Ltd | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. |
| WO2021142736A1 (en) * | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Dosing regimen of glp-1 |
| WO2021142733A1 (en) | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
| JPS6350793A (ja) | 1986-08-20 | 1988-03-03 | 株式会社東芝 | 高速増殖炉の崩壊熱除去システム |
| US5034415A (en) | 1987-08-07 | 1991-07-23 | Century Laboratories, Inc. | Treatment of diabetes mellitus |
| EP0351651B1 (en) | 1988-07-21 | 1993-09-15 | F. Hoffmann-La Roche Ag | Insulin preparation |
| JPH02250823A (ja) | 1989-03-24 | 1990-10-08 | Tsumura & Co | マイクロカプセル剤およびその製造方法 |
| GB9007052D0 (en) | 1990-03-29 | 1990-05-30 | Skua Investments Ltd | Pharmaceutical formulations |
| US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
| DE69333025T2 (de) * | 1992-11-17 | 2004-04-29 | E.I. Du Pont De Nemours And Co., Wilmington | Für mikrosom delta 12 fettsäuredesaturase kodierende gene und verwandte enzyme von pflanzen |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| IL114673A (en) | 1995-07-19 | 2000-12-06 | Hadasit Med Res Service | Pharmaceutical compositions containing protein for oral administration |
| JPH09208485A (ja) | 1996-01-31 | 1997-08-12 | Teijin Ltd | ペプチド・蛋白質性薬物の水難溶性組成物 |
| DE69740096D1 (de) | 1996-08-08 | 2011-02-17 | Amylin Pharmaceuticals Inc | Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid |
| JPH10330287A (ja) | 1997-03-31 | 1998-12-15 | Nippon Suisan Kaisha Ltd | 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤 |
| JP2000128805A (ja) | 1998-10-27 | 2000-05-09 | Nippon Suisan Kaisha Ltd | 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤 |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| CZ305123B6 (cs) * | 1999-10-04 | 2015-05-13 | Novartis Vaccines And Diagnostics, Inc. | Způsob výroby kapalného farmaceutického prostředku |
| JP2001240558A (ja) | 2000-02-29 | 2001-09-04 | Nippon Suisan Kaisha Ltd | 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。 |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| KR20010069322A (ko) | 2001-03-08 | 2001-07-25 | 서종수 | 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법 |
| KR20010069433A (ko) | 2001-03-22 | 2001-07-25 | 김윤완 | 노루궁뎅이버섯을 이용한 건강 보조 식품 |
| CN1160122C (zh) | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
| CN1741805A (zh) | 2001-07-18 | 2006-03-01 | 索莱有限责任公司 | 高蛋白质鲍曼－比尔克抑制剂浓缩物及其生产方法 |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US20050143303A1 (en) | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| CN101027318B (zh) | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物，制剂及其用途 |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| EP1789075A4 (en) | 2004-08-25 | 2009-07-01 | Uab Research Foundation | ABSORPTION ENHANCER FOR DRUG ADMINISTRATION |
| DK1814590T4 (da) * | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals Llc | Behandling af obesitet og beslægtede sygdomme. |
| US8389472B2 (en) * | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| EP2722054B1 (en) | 2005-09-06 | 2018-03-21 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| US20070086972A1 (en) | 2005-09-12 | 2007-04-19 | Jacob Birnbaum | Hair growth compositions and methods for treating hair loss or related conditions |
| US20070077283A1 (en) | 2005-09-30 | 2007-04-05 | Nastech Pharmaceutical Company Inc. | Method of enhancing transmucosal delivery of therapeutic compounds |
| CN101095942B (zh) | 2006-06-30 | 2011-11-16 | 北京民海生物科技有限公司 | 一种包含稳定剂的Exendin-4注射剂药物配方 |
| WO2008142482A2 (en) | 2006-11-01 | 2008-11-27 | Pronova Biopharma Norge As | Omega-3 lipid compounds |
| PL2144618T5 (pl) | 2007-03-28 | 2025-07-21 | Aker Biomarine Human Ingredients As | Bio-skuteczne kompozycje oleju z kryla |
| RU2504373C2 (ru) * | 2008-03-26 | 2014-01-20 | ОРАМЕД Лтд. | Способы и композиции для перорального введения протеинов |
| CA2723434C (en) * | 2008-05-05 | 2018-01-23 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| JPWO2009151125A1 (ja) * | 2008-06-13 | 2011-11-17 | 持田製薬株式会社 | 肝障害の診断及び治療 |
| WO2009154230A1 (ja) | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
| ES2558842T3 (es) * | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| WO2010002418A2 (en) | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Quick-dissolving oral thin film for targeted delivery of therapeutic agents |
| CN102123697B (zh) * | 2008-08-18 | 2015-06-10 | 安特拉贝欧有限公司 | 用于口服给予蛋白质的方法和组合物 |
| UY32177A (es) | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
| KR101783817B1 (ko) | 2009-05-08 | 2017-10-23 | 프로노바 바이오파마 너지 에이에스 | 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산 |
| US20120202849A1 (en) | 2009-10-12 | 2012-08-09 | Anil Pareek | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
| CN103988973A (zh) | 2009-12-30 | 2014-08-20 | 索莱有限责任公司 | 大豆乳清蛋白组合物及其回收方法 |
| US20130273154A1 (en) | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| PH12012502524A1 (en) * | 2010-06-24 | 2014-02-10 | Boehringer Ingelheim Int | Diabetes therapy |
| CA2804506C (en) * | 2010-07-06 | 2018-08-21 | Janssen Pharmaceutica Nv | Formulation for co-therapy treatment of diabetes |
| ES2659763T3 (es) * | 2011-02-14 | 2018-03-19 | The Regents Of The University Of Michigan | Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| CN102219850A (zh) * | 2011-05-03 | 2011-10-19 | 上海格尼生物技术有限公司 | 新的长效glp-1化合物 |
| US20140220134A1 (en) * | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
| WO2013010289A1 (zh) | 2011-07-15 | 2013-01-24 | Chan Tu Cheng | 填充式工件表面饰化方法 |
| US9458214B2 (en) * | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| WO2013102899A1 (en) | 2012-01-03 | 2013-07-11 | Oramed Ltd. | Methods and compositions for treating diabetes |
| ES2912138T3 (es) * | 2012-02-01 | 2022-05-24 | Oramed Ltd | Composiciones que contienen inhibidores de proteasa, composiciones que comprenden las mismas y métodos para producir y usar las misma |
| WO2013148966A1 (en) * | 2012-03-28 | 2013-10-03 | Amylin Pharmaceuticals, Llc | Transmucosal delivery of engineered polypeptides |
| CN104902921A (zh) * | 2013-01-03 | 2015-09-09 | 奥拉姆德有限公司 | 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物 |
-
2014
- 2014-01-02 CN CN201480003919.4A patent/CN104902921A/zh active Pending
- 2014-01-02 EP EP22205280.5A patent/EP4215205A1/en not_active Withdrawn
- 2014-01-02 WO PCT/IL2014/050007 patent/WO2014106846A2/en not_active Ceased
- 2014-01-02 EP EP14735143.1A patent/EP2941267B1/en active Active
- 2014-01-02 JP JP2015551250A patent/JP2016505613A/ja active Pending
- 2014-01-02 CN CN201910287860.0A patent/CN110151979A/zh active Pending
- 2014-01-02 US US14/759,060 patent/US20150335715A1/en not_active Abandoned
-
2018
- 2018-07-11 JP JP2018131875A patent/JP2018197240A/ja active Pending
- 2018-11-19 US US16/195,184 patent/US10967051B2/en active Active
-
2020
- 2020-06-12 JP JP2020102461A patent/JP2020180126A/ja active Pending
-
2021
- 2021-03-19 US US17/206,574 patent/US20220000986A1/en not_active Abandoned
-
2022
- 2022-09-29 JP JP2022156787A patent/JP2023002570A/ja active Pending
-
2023
- 2023-12-21 US US18/392,074 patent/US20240181018A1/en not_active Abandoned
-
2025
- 2025-03-13 JP JP2025040577A patent/JP2025106279A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018197240A5 (enExample) | ||
| HK1247835A1 (zh) | 甲状旁腺功能减退症的治疗 | |
| JP2012500254A5 (enExample) | ||
| JP2018504445A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2018504444A5 (ja) | 医薬組成物 | |
| HRP20180425T1 (hr) | Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline | |
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| RU2013130611A (ru) | Способы и композиции для перорального введения белков | |
| CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| RU2010146372A (ru) | Композиции и способы перорального введения эксенатида | |
| AR105809A1 (es) | Compuestos para el tratamiento de trastornos médicos | |
| WO2010121128A3 (en) | Compositions and methods for treating or inhibiting liver injury | |
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| MX348282B (es) | Formulaciones farmaceuticas de liberacion controlada de nitazoxanida. | |
| AR105319A1 (es) | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico | |
| RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
| JP2011026348A5 (enExample) | ||
| JP2016516773A5 (enExample) | ||
| BR112015019264A8 (pt) | cápsulas para o tratamento de helicobacter pylori e seu uso". | |
| MX2013006187A (es) | Composiciones farmaceuticas. | |
| BR112012003907A2 (pt) | composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês | |
| PH12022551148A1 (en) | Injectable compositions of ursodeoxycholic acid | |
| CN112245419A (zh) | 包括15-hepe的组合物以及使用其治疗或预防纤维化的方法 | |
| HRP20241491T1 (hr) | Pripravci i metode za liječenje homocistinurije |